Results 181 to 190 of about 3,909 (222)
Some of the next articles are maybe not open access.
Terlipressin in Hepatorenal Syndrome
Annals of Pharmacotherapy, 2011Objective: To compare the pharmacology, dosing, and adverse reactions of vasopressin and terlipressin for the treatment of hepatorenal syndrome (HRS) and assess the efficacy of the investigational drug terlipressin for HRS. Data Sources: Articles evaluating prospective studies for vasopressin and terlipressin were discussed after being identified ...
Joseph F. Dasta +2 more
openaire +2 more sources
Terlipressin in the management of liver disease
Expert Opinion on Pharmacotherapy, 2023Terlipressin is a synthetic vasopressin analog which has been recently approved in the United States by the Food and Drug Administration for the treatment of hepatorenal syndrome. Terlipressin stimulates vasopressin receptors located on the smooth muscle vasculature of the splanchnic circulation and renal tubules which results in splanchnic ...
Andrew R Scheinberg +2 more
openaire +2 more sources
Terlipressin in brain‐death donors
Clinical Transplantation, 2012AbstractBackgroundMetabolic management of brain‐death organ donors includes correction of the hormonal perturbations that occur after cerebral death and impair circulatory function. Vasopressin is a hormone secreted by the posterior pituitary gland, which contributes to maintain systemic blood pressure by regulating urine secretion and small arteriole ...
Michele Iannuzzi +6 more
openaire +6 more sources
Terlipressin for hepatorenal syndrome
2012Clinical trials suggest that terlipressin improves renal function in hepatorenal syndrome, but the evidence concerning mortality is equivocal.To assess the beneficial and harmful effects of terlipressin alone or with albumin versus placebo, no intervention or albumin for hepatorenal syndrome.Eligible trials were identified through electronic (The ...
Gluud, Lise Lotte +3 more
openaire +3 more sources
Terlipressin-induced hyponatremic seizure
Scandinavian Journal of Gastroenterology, 2010Terlipressin is a splanchnic constrictor that is used to control variceal bleeding and is considered to have a very good safety profile compared to vasopressin. However, side effects such as hyponatremia and seizure, although very rare, can occur. Recently, the authors have experienced a case of hyponatremia induced by infusion of terlipressin which ...
Soon Ho Um +9 more
openaire +3 more sources
Terlipressin for hepatorenal syndrome
2006Terlipressin may reverse some of the circulatory changes associated with hepatorenal syndrome.To assess the beneficial and harmful effects of terlipressin for hepatorenal syndrome.Electronic searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Renal Group Register, the Cochrane Central Register of Controlled Trials in ...
L L, Gluud, M S, Kjaer, E, Christensen
openaire +2 more sources
Terlipressin-induced ventricular arrhythmia
Scandinavian Journal of Gastroenterology, 2008During intravenous treatment with terlipressin for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes. Risk factors present for acquired long QT syndrome were mineral dysbalance and a history of alcohol abuse with hepatic impairment.
Karel Urbánek +3 more
openaire +3 more sources
Hyponatraemia during terlipressin therapy
Gut, 2010We have read with interest the study by Lo et al 1 in a recent issue of Gut . Apart from the findings that short-term therapy with terlipressin in combination with ligation seems to improve outcome in bleeding oesophageal varices (BOVs) compared to longer treatment with terlipressin, a shorter treatment period with terlipressin most likely reduces the ...
Krag, Aleksander +3 more
openaire +4 more sources
Formulary Drug Reviews: Terlipressin
Hospital Pharmacy, 2023Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
openaire +2 more sources
Terlipressin (Terlivaz) for Hepatorenal Syndrome
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved the intravenously administered synthetic vasopressin analog terlipressin (Terlivaz – Mallinckrodt) to improve kidney function in adults with hepatorenal syndrome (HRS) and a rapid decline in kidney function. Terlipressin is the first drug to be approved for this indication in the US; it has been available in Europe and elsewhere ...
openaire +2 more sources